Gene Therapy Casgevy denied for failing step therapy by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for gene therapy casgevy are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## UnitedHealthcare Step Therapy Denial for Casgevy — Why It Happens and How to Appeal

Casgevy (exagamglogene autotemcel) is a gene therapy approved for sickle cell disease and transfusion-dependent beta-thalassemia in patients who have not responded adequately to available treatments. A step therapy denial means UHC is requiring documented prior use — and often failure — of one or more other treatments before approving Casgevy. Understanding exactly what steps are required, and how to demonstrate you have met them, is the key to overturning this denial.

## Why Step Therapy Denials Happen Here

Gene therapy is positioned as a higher-intensity option after other management strategies have been tried. UHC's coverage policy for Casgevy specifies the conditions under which step therapy requirements are considered satisfied. Common reasons for step therapy denial include: prior therapies not documented in the submitted records, records lacking outcome data (i.e., they show the drug was prescribed but not that it failed), or documentation gaps around the duration or adequacy of prior treatment trials.

## Step Therapy Override Rights

Most states have enacted step therapy reform laws requiring insurers to grant overrides when: (1) the required therapy is contraindicated or would cause adverse effects; (2) the required therapy has already been tried and failed; or (3) the required therapy is not in the patient's best clinical interest. Your state insurance commissioner's website will list your specific state's protections. Even absent state law, UHC's own policy must provide an exceptions process.

## Federal Appeal Framework

• Internal appeal: File within 180 days of denial. Response due in 30 days (standard) or 72 hours (expedited).
• External review (ACA §2719): After exhausting internal appeals, request IRO review — window is approximately 4 months from final internal denial.
• ERISA §503: Employer-sponsored plan members have federally guaranteed full-and-fair review rights.
• Expedited review: Available if delay poses serious health risk; request explicitly in writing.

## Documentation to Gather

1. Prior treatment history: Dated records of every relevant therapy previously tried — including start/end dates, documented clinical response, and reason for discontinuation or change. 2. Failure documentation: Prescriber notes, lab values, hospitalizations, or other objective evidence that prior required therapies did not achieve adequate clinical control. 3. Medical necessity letter: Your treating hematologist should address each step in UHC's policy, confirming which steps have been completed and why Casgevy is the appropriate next therapy. 4. UHC coverage policy: Download the current version of UHC's medical/coverage policy for Casgevy and identify every step required. Address each one explicitly. 5. FDA prescribing label: Confirm the approved indication and any populations for whom prior-therapy requirements are already built into the label.

## Criteria-Mapping Structure

| UHC Step Requirement | Documented Evidence of Completion | |---|---| | Prior therapy 1 tried and failed | Chart notes + dates + outcome documented | | Prior therapy 2 tried and failed (if applicable) | Chart notes + dates + outcome documented | | Duration/adequacy of each trial | Prescriber confirmation of adequate trial | | Clinical rationale for Casgevy now | Specialist letter addressing UHC's policy criteria |

A step therapy appeal that maps each prior-therapy requirement to a specific chart entry — with dates, prescriber attestation, and documented outcomes — is far more likely to succeed than a general letter.